Omeprazol Krka (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production.
• Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics.
• NSA‑ID‑associated ulcer prophylaxis: lowers risk of ulcer development in high‑risk patients.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By irreversibly binding to this pump, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduction of gastric acidity.

Omeprazole is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually transient.
• Abdominal pain or discomfort: occasional.
• Nausea or vomiting: may occur early in therapy.
• Flatulence: mild bloating.
• Constipation: infrequent.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis risk.
• Acute interstitial nephritis: renal inflammation.
• Hypomagnesemia: low serum magnesium levels.
• Fracture risk: possible decrease in bone mineral density with long‑term use.
• Stevens‑Johnson syndrome/TEN: rare severe skin reactions.
• Hepatotoxicity: elevated liver enzymes or hepatitis.

Before initiating Omeprazole, consider patient‑specific factors and monitoring requirements.

• Assess renal and hepatic function: adjust use if impairment is present.
• Review concomitant medications: potential for altered absorption or metabolism.
• Use the lowest effective dose: limit duration to the shortest necessary period.
• Monitor for vitamin B12 deficiency: long‑term therapy may impair absorption.
• Evaluate bone health: consider calcium and vitamin D supplementation if therapy exceeds 12 months.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atorvastatin: increased plasma concentrations, heightened risk of myopathy.
• Warfarin: enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely)

• Digoxin: increased serum levels, watch for toxicity signs.
• Methotrexate: reduced renal clearance, risk of accumulation.
• HIV protease inhibitors (e.g., ritonavir): altered exposure, adjust dosing as needed.